## Scientific Programme - EAU20

### Common problems in onco-urology

Joint meeting of the EAU Section of Oncological Urology (ESOU), the EAU Robotic Urology Section (ERUS), the EAU Section of Uro-Technology (ESUT) and with the ECCO, EORTC GUCG, ESMO, ESSO, ESTRO and EUOG

**Saturday 18 July**

10:30 - 15:15

**Location:** Orange Area, eURO Auditorium 2

**Chairs:** G. Giannarini, Udine (IT)  
S. Joniau, Leuven (BE)

**Learning objectives of this session**

- To promote the role of European urologists as principal caregivers in the field of Genito Urinary cancers.
- To advance care across the spectrum of GU cancers.
- To highlight scientific alliance between EAU sections and other scientific associations where borders between the roles of oncologists, radiotherapists and urologists are non-existent.

### 10:30 - 10:35

**Welcome and introduction**

G. Giannarini, Udine (IT)  
S. Joniau, Leuven (BE)

### 10:35 - 10:50

**The European Uro-Oncology Group (EUOG)**

**10:35 - 10:45**

First-line treatment AR inhibitor in mHSPC: Optimizing staging and response monitoring

To be confirmed

**10:45 - 10:50**

Discussion

### 10:50 - 11:00

**Neo adjuvant or adjuvant chemotherapy in upper urinary tract cancer?**

J. Palou, Barcelona (ES)

### 11:00 - 11:15

**The European Cancer Organisation (ECCO)**

**11:00 - 11:10**

ECCO amplifying the work of its member societies in EU policy and advocacy

To be confirmed

**11:10 - 11:15**

Discussion

### 11:15 - 11:30

**The European Society for Radiotherapy & Oncology (ESTRO)**

**11:15 - 11:25**

Salvage treatment after failure of radiotherapy in localised prostate cancer

To be confirmed

**11:25 - 11:30**

Discussion

### 11:30 - 11:45

**The European Society for Medical Oncology (ESMO)**

**11:30 - 11:40**

Current landscape of first-line systemic treatment in metastatic renal cell carcinoma

L. Albiges, Villejuif (FR)

**11:40 - 11:45**

Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45 - 12:00</td>
<td>The European Organisation for Research and Treatment of Cancer Genito-Urinary Cancer Group (EORTC GUCG)</td>
</tr>
<tr>
<td>11:45 - 11:55</td>
<td>Influence of the intake of statin on the outcome of prostate cancer To be confirmed</td>
</tr>
<tr>
<td>11:55 - 12:00</td>
<td>Discussion</td>
</tr>
<tr>
<td>12:00 - 12:15</td>
<td>The European Society of Surgical Oncology (ESSO)</td>
</tr>
<tr>
<td>12:00 - 12:10</td>
<td>Lymph node management in penile cancer: Controversies and developments M. Albersen, Leuven (BE)</td>
</tr>
<tr>
<td>12:10 - 12:15</td>
<td>Discussion</td>
</tr>
<tr>
<td>12:15 - 12:25</td>
<td>The European Association of Urology Nurses (EAUN): The follow up of renal cell cancer by the ANP in relation to the quality of care and efficiency of care To be confirmed</td>
</tr>
<tr>
<td>12:25 - 15:05</td>
<td>ESOU-ESUT-ERUS: Evidence-based case debates and controversies in onco-urology Moderators: A.E. Canda, Istanbul (TR) To be confirmed To be confirmed</td>
</tr>
<tr>
<td>12:25 - 12:45</td>
<td>Debate  The role of robotic surgery: Is there still room for training young surgeons to open surgery in 2019?</td>
</tr>
<tr>
<td>12:45 - 13:10</td>
<td>Debate  Do we have to recommend the robotic approach systematically to perform a partial nephrectomy?</td>
</tr>
<tr>
<td>13:10 - 13:20</td>
<td>Questions and answers</td>
</tr>
<tr>
<td>13:20 - 13:45</td>
<td>Debate  The medico legal standpoint: A renal biopsy is mandatory in any renal cell carcinoma</td>
</tr>
<tr>
<td>13:45 - 13:55</td>
<td>Questions and answers</td>
</tr>
<tr>
<td>13:55 - 14:20</td>
<td>Debate  Is there a right timing for molecular imaging in castration resistant prostate cancer?</td>
</tr>
<tr>
<td>14:20 - 14:30</td>
<td>Questions and answers</td>
</tr>
<tr>
<td>14:30 - 14:55</td>
<td>Debate  There is no role for radical cystectomy in cT0 after neoadjuvant chemotherapy</td>
</tr>
<tr>
<td>14:55 - 15:05</td>
<td>Discussion</td>
</tr>
<tr>
<td>15:05 - 15:10</td>
<td>Closing remarks To be confirmed</td>
</tr>
</tbody>
</table>